June 26, 2026 02:19 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi | Taratala warehouse collapse: Death toll climbs to 8, five arrested as SIT launches probe | Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners | Passport is a travel document, not conclusive proof of citizenship: MEA | Kolkata: Taratala warehouse roof collapses | Indian Army's Trishakti Corps restores lifeline connectivity in North Bengal between Siliguri and Mirik | 19 million barrels flow through Strait of Hormuz, Trump declares oil prices are falling | No Hindi, no NEET: Vijay reignites Tamil Nadu's biggest political flashpoints | Messi creates World Cup history with record-breaking double; Mbappe equals Klose's mark hours later | Tech giant Oracle slashes 21,000 jobs while betting big on AI
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.